Similar articles

• Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C.

  Kanda T, Yokosuka O. Kanda T, et al. JNMA J Nepal Med Assoc. 2011 Jan-Mar;51(181):41-8. JNMA J Nepal Med Assoc. 2011. PMID: 22335095 Review.
• [Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].

  [No authors listed] [No authors listed] MMW Fortschr Med. 2002 Sep 19;144(38):59. MMW Fortschr Med. 2002. PMID: 12395712 German. No abstract available.
• The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.

  Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, Pastore G, Trejo-Estrada R, Horta E Vale A, Wintfeld N, Green J. Hassanein T, et al. J Hepatol. 2004 Apr;40(4):675-81. doi: 10.1016/j.jhep.2003.12.014. J Hepatol. 2004. PMID: 15030985 Clinical Trial.
• Peginterferon alfa-2b plus ribavirin for chronic hepatitis.

  Santin M, Shaw E. Santin M, et al. Lancet. 2002 Jan 19;359(9302):263; author reply 264. doi: 10.1016/S0140-6736(02)07428-7. Lancet. 2002. PMID: 11812596 No abstract available.
• Peginterferon alfa-2a (40KD) (Pegasys) for the treatment of patients with chronic hepatitis C.

  Ferenci P. Ferenci P. Int J Clin Pract. 2003 Sep;57(7):610-5. Int J Clin Pract. 2003. PMID: 14529063 Review.